Cargando…
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167863/ https://www.ncbi.nlm.nih.gov/pubmed/32050707 http://dx.doi.org/10.3390/biology9020028 |
_version_ | 1783523604968767488 |
---|---|
author | Zaytsev, Daniil Girshova, Larisa Ivanov, Vladimir Budaeva, Irina Motorin, Dmitri Badaev, Renat Mirolubova, Julia Grobovenko, Evgeni Chitanava, Tamara Zaykova, Ekaterina Alexeeva, Julia Zaritskey, Andrey |
author_facet | Zaytsev, Daniil Girshova, Larisa Ivanov, Vladimir Budaeva, Irina Motorin, Dmitri Badaev, Renat Mirolubova, Julia Grobovenko, Evgeni Chitanava, Tamara Zaykova, Ekaterina Alexeeva, Julia Zaritskey, Andrey |
author_sort | Zaytsev, Daniil |
collection | PubMed |
description | Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never been reported. This study aimed to demonstrate the efficacy and rapid response of Gemtuzumab ozogamicin in refractory acute myeloid leukemia (AML) patients with pulmonary and kidney failure and poor performance status. Three refractory AML patients, with organ dysfunction, are described. One patient was pre-treated with intensive chemotherapy, and two other patients progressed during Azacitidine treatment. Two patients had respiratory failure grade 2 and one patient suffered from acute kidney insufficiency. Two patients were highly febrile with an elevated С-Reactive Protein (CRP) level. The WHO performance status of three was measured in all patients. Gemtuzumab ozogamicin administration was performed in three patients, followed by a further switch to Gemtuzumab ozogamicin + Azacitidine or “7+3” treatment. Results: Gemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with a rapid decrease in CRP level and fast resolution of respiratory failure. Recovery of kidney function was noticed rapidly in patients with renal insufficiency. The WHO performance status was elevated in all three patients. No adverse grade II–III effects were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient underwent allogeneic stem cell transplantation, and the patient with kidney failure obtained complete remission. Conclusions: Gemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunction, like pulmonary or renal failure and poor performance status, and may contribute to rapid recovery from organ failures. |
format | Online Article Text |
id | pubmed-7167863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71678632020-04-21 Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure Zaytsev, Daniil Girshova, Larisa Ivanov, Vladimir Budaeva, Irina Motorin, Dmitri Badaev, Renat Mirolubova, Julia Grobovenko, Evgeni Chitanava, Tamara Zaykova, Ekaterina Alexeeva, Julia Zaritskey, Andrey Biology (Basel) Case Report Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover, the fast recovery from organ failure, after Gemtuzumab ozogamicin administration, has never been reported. This study aimed to demonstrate the efficacy and rapid response of Gemtuzumab ozogamicin in refractory acute myeloid leukemia (AML) patients with pulmonary and kidney failure and poor performance status. Three refractory AML patients, with organ dysfunction, are described. One patient was pre-treated with intensive chemotherapy, and two other patients progressed during Azacitidine treatment. Two patients had respiratory failure grade 2 and one patient suffered from acute kidney insufficiency. Two patients were highly febrile with an elevated С-Reactive Protein (CRP) level. The WHO performance status of three was measured in all patients. Gemtuzumab ozogamicin administration was performed in three patients, followed by a further switch to Gemtuzumab ozogamicin + Azacitidine or “7+3” treatment. Results: Gemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with a rapid decrease in CRP level and fast resolution of respiratory failure. Recovery of kidney function was noticed rapidly in patients with renal insufficiency. The WHO performance status was elevated in all three patients. No adverse grade II–III effects were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient underwent allogeneic stem cell transplantation, and the patient with kidney failure obtained complete remission. Conclusions: Gemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunction, like pulmonary or renal failure and poor performance status, and may contribute to rapid recovery from organ failures. MDPI 2020-02-10 /pmc/articles/PMC7167863/ /pubmed/32050707 http://dx.doi.org/10.3390/biology9020028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Zaytsev, Daniil Girshova, Larisa Ivanov, Vladimir Budaeva, Irina Motorin, Dmitri Badaev, Renat Mirolubova, Julia Grobovenko, Evgeni Chitanava, Tamara Zaykova, Ekaterina Alexeeva, Julia Zaritskey, Andrey Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title | Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title_full | Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title_fullStr | Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title_full_unstemmed | Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title_short | Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure |
title_sort | rapid efficacy of gemtuzumab ozogamicin in refractory aml patients with pulmonary and kidney failure |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167863/ https://www.ncbi.nlm.nih.gov/pubmed/32050707 http://dx.doi.org/10.3390/biology9020028 |
work_keys_str_mv | AT zaytsevdaniil rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT girshovalarisa rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT ivanovvladimir rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT budaevairina rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT motorindmitri rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT badaevrenat rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT mirolubovajulia rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT grobovenkoevgeni rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT chitanavatamara rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT zaykovaekaterina rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT alexeevajulia rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure AT zaritskeyandrey rapidefficacyofgemtuzumabozogamicininrefractoryamlpatientswithpulmonaryandkidneyfailure |